More on NCEL
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $2.82 |
|
|||
| Open | $2.85 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $2.85 | ||||
| Day Low | $2.75 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 7,734 | ||||
- Form 6-K NewcelX Ltd. For: Feb 12
- NewcelX publishes peer-reviewed study on Mazindol ER therapy
- NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy
- Form 6-K NewcelX Ltd. For: Jan 29
- NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences
- Form 6-K NewcelX Ltd. For: Jan 12
- NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression
- Form 6-K NewcelX Ltd. For: Jan 05
- NewcelX appoints diabetes expert to scientific advisory board
- NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board
Entities mentioned with NCEL
- Definitive Agreement | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- 13G | View Related Stories »
- 13D | View Related Stories »
- Show More...
